Skip To Main Content
Anne Pernille Harlem on Muck Rack

Anne Pernille Harlem

As seen in: Frontiers, Diagnostic Pathology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anne Pernille

Contact Anne Pernille, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CD73 expression as a resistance mechanism in advanced EGFR-mutated non-small cell lung cancer

|
By Inger Johanne Zwicky, Anne Pernille Harlem, Odd Terje
| Frontiers
Abstract Introduction: The ectoenzyme CD73 induces an immune-evasive tumor microenvironment and has been proposed to be modulated by EGFR-TKI treatment. In this exploratory study, we analyzed CD73 expression and related immune markers during sequenced EGFR-TKI treatment, including osimertinib, to identify potential biomarkers for CD73-based therapeutic opportunities in EGFR-resistant tumors.
Open in Who Shared Issue with article?

“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer” - Diagnostic Pathology

|
By Anne Pernille Harlem, Abdirashid Ali, Marianne Odnakk, Joakim Oliu
| Diagnostic Pathology Verified
In this study we aimed to map the prevalence of ROS1 rearrangement in a Norwegian cohort of early-stage resectable lung cancer, and see whether the tumours with ROS1 fusion or ROS1 protein expression were associated with specific epidemiological, histological or genetic characteristics. The prevalence of ROS1 fusion in resected adenocarcinomas in this cohort was 0.6%.
Open in Who Shared Issue with article?
See all 2 articles